Law360, New York (June 28, 2012, 8:33 PM ET) -- A U.S. Food and Drug Administration advisory panel recommended Thursday that the labeling for metal-on-metal hip implants, the target of multiple recalls and massive litigation, include warnings for tumor-like growths and elevated metal ion levels in the bloodstream.
The FDA convened a group of orthopedic surgeons, medical experts, industry representatives and patient advocates for a two-day meeting to review the available safety data for the devices. During Wednesday's session, Johnson & Johnson unit DePuy Orthopaedics Inc. and other implant makers urged the panel not to consider...
FDA Panel Calls For More Warnings On Metal Hip Implants
To view the full article, take a free trial now.
